Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
6 Leser
Artikel bewerten:
(0)

Global Gene Therapy Market Outlook to 2018

DUBLIN, May 19, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/zkh432/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2018 " report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market, presenting a few marketable products and being nascent in terms of revenue generation, holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2018, as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.

According to this new research report Global Gene Therapy Market Outlook 2018, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the gene therapy market such as phases, geographies, vector types, etc.

Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments in gene therapy include cardiac conditions, inherited blindness, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report.

Also, a brief overview of the key geographies in the gene therapy market and the regulatory scenario governing the industry has been included to present a balanced outlook. Unlike other regions globally, the United States continues to have the maximum number of clinical trials in the gene therapy segment. This shows the country's potential to become a leader in gene therapy in the coming years.

The author, in its report, further covers how major trends and drivers, including gene silencing, advanced therapies, etc., will propel the industry's growth. However, an analysis has been done of a few factors limiting the growth of the industry. Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction

4. Industry Trends and Drivers

5. Market Restraints

6. Gene Therapy Market Outlook

7. Gene Therapy Market - Regulatory Landscape

8. Advanced Gene Therapy Drugs

9. Mergers and Acquisitions

10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People)

- Advantagene Inc
- Bluebird Bio
- Genethon
- Genzyme - A Sanofi Company
- Kolon Life Science
- Oxford BioMedica
- Sanofi
- Spark Therapeutics, LLC
- Vical Inc
- ViroMed Co. Ltd. dba VM BioPharma

For more information visit http://www.researchandmarkets.com/research/zkh432/global_gene

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.